Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.31 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16488240 | 0.98 | PIM3 (0.35) | PIM3PTPN7DUSP3PTPN12PTPN22 | |
| SCHEMBL16488251 | 0.98 | PIM3 (0.35) | PIM3PTPN7DUSP3PTPN12PTPN22 | |
| SCHEMBL13827268 | 0.97 | PIM3 (0.36) | PIM3PTPN7DUSP3PTPN12PTPN22 | |
| SCHEMBL13557657 | 0.97 | GPR3 (0.32) | PTPN7DUSP3PTPN12PTPN22GPR3 | |
| SCHEMBL13557575 | 0.95 | GPR3 (0.34) | PTPN7DUSP3PTPN12PTPN22GPR3 | |
| SCHEMBL13827316 | 0.94 | PIM3 (0.34) | PIM3PTPN7DUSP3PTPN12PTPN22 | |
| SCHEMBL13827310 | 0.94 | PIM3 (0.34) | PIM3PTPN7DUSP3PTPN12PTPN22 | |
| SCHEMBL13557659 | 0.94 | PIM3 (0.33) | PIM3PTPN7DUSP3PTPN12PTPN22 | |
| SCHEMBL16488249 | 0.94 | GPR3 (0.33) | PIM3PTPN7DUSP3PTPN12PTPN22 | |
| SCHEMBL13557581 | 0.94 | GPR3 (0.33) | PIM3PTPN7DUSP3PTPN12PTPN22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120273766-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-11-01 | — | — | US | disclosed |
| US-20120273766-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120273766-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | DDC, ODC1, TYR | PIM3 715/4885PTPN7 4082/4885DUSP3 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.